UroGen Pharma (NASDAQ: URGN) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of $(0.48) by 2.08 percent. This is a 48.91 percent increase over losses of $(0.92) per share from the same period last year. The company reported quarterly sales of $50.959 million which beat the analyst consensus estimate of $44.820 million by 13.70 percent. This is a 151.60 percent increase over sales of $20.254 million the same period last year.